	Trial	Trial type	N SGLT2-inhibitor (final study cohorts) ¹ Canagliflozin Empagliflozin Any					N DPP4-inhibitor (fnal study cohorts) ¹ Sita- Alogliptin Lina- Any					Any			Study time period	Inclusion criteria ²
			100mg	Canagliflozin 100mg 300mg		Empagliflozin 10mg 25mg		Sita- gliptin Alogliptin 100mg 6.25mg		n 12.5mg 25mg		gliptin 5mg	Any DPP4-i				
1	CANTATA-D (NCT01106677)	Efficacy, placebo- controlled and active comparator	352	353			705	355					355	Immediate-release metformin monotherapy (≥2,000 mg/day, or ≥1,500 mg/day if unable to tolerate higher dose). (Participants on sulfonylurea in addition to metformin discontinued sulfonylurea.)	HbA1c change from baseline to 26 weeks	April 2010- August 2012	 Aged 18-80 HbA1c ≥7% and ≤10.5% Currently treated with metformin (maximum dose) alone or combined with sulfonylurea Exclusion: Uncontrolled hyperglycaemia defined as repeated FPG ≥15.5mmol/L Uncontrolled hypertension eGFR <55mL/min (or <60 mL/min if based upon restriction in local label) or serum creatinine ≥124 µmol/L (men) or ≥115 µmol/L (women) Treatment with PPAR-γ agonist, insulin, another SGLT2-inhibitor or any other antihyperglycaemic agents except metformin alone or with sulfonylurea within 12 weeks Cardiovascular disease including MI, unstable angina, revascularisation procedure or cerebrovascular accident within 3 months Severe hypoglycaemia episode within 6 months
2	CANTATA-D2 (NCT01137812)	Efficacy, placebo- controlled and active comparator		359			359	356					356	Combined metformin and sulfonylurea at maximum- or near- maximum doses (adjusted pre-run in if not already at these doses)	HbA1c change from baseline to 52 weeks	June 2010- March 2012	 Aged 18+ HbA1c ≥7% and ≤10.5% Currently treated with metformin alone or combined with sulfonylurea Exclusion: Uncontrolled hyperglycaemia defined as repeated FPG ≥16.7mmol/L Uncontrolled hypertension eGFR <55mL/min (or <60 mL/min if based upon restriction in local label) or serum creatinine ≥124 µmol/L (men) or ≥115 µmol/L (women) Treatment with PPAR-γ agonist, insulin, another SGLT2-inhibitor or any other antihyperglycaemic agents except metformin and sulfonylurea within 12 weeks History of cardiovascular disease Severe hypoglycaemia episode within 6 months
3	EMPA-REG MONO (BI1245.20; NCT01177813)	Efficacy, placebo- controlled and active comparator			214	291	505	219					219	None (drug-naïve)	HbA1c change from baseline to 24 weeks	August 2010- March 2012	 Aged 18+ (20+ in Japan only) HbA1c ≥7% and ≤10% BMI ≤45kg/m² Drug-naïve to antihyperglycaemic agents Exclusion: Uncontrolled hyperglycaemia after overnight fast during placebo run-in eGFR <50mL/min at screening/placebo run-in Current treatment with systemic steroids or change in dosage of thyroid hormones within 6 weeks or any uncontrolled endocrine disorder except T2D Treatment with anti-obesity medication/other treatment leading to unstable body weight Any acute coronary syndrome], stroke, TIA within 3 months Bariatric/other GI surgeries within 2 years History of cancer Any disorders causing haemolysis or unstable red blood cells
4	CANTATA-SU (NCT00968812)	Efficacy, active comparator (sulfonylurea)	470	469			939							Immediate-release metformin monotherapy (≥2,000 mg/day, or ≥1,500 mg/day if unable to tolerate higher dose). (Participants on combined metformin and a second antihyperglycaemic agent (not TZD as per inclusion criteria) discontinued second agent.)	HbA1c change from baseline to 52 weeks	August 2009- December 2011 (core period) or January 2013 (52-week extension)	 Aged 18-80 HbA1c ≥7% and ≤9.5% BMI ≥22 and ≤45kg/m² Currently treated with metformin (maximum dose) alone or combined with another antihyperglycaemic agent Exclusion: Uncontrolled hyperglycaemia defined as repeated FPG ≥15mmol/L History of active proliferative diabetic retinopathy eGFR <55mL/min (or <60 mL/min if based upon restriction in local label) or serum creatinine ≥124 µmol/L (men) or ≥115 µmol/L (women) Treatment with TZD within 16 weeks Hereditary glucose-galactose malabsorption or primary renal glucosuria Renal disease requiring immunosuppressive therapy within 12 months or a history of dialysis or renal transplant Severe hypoglycaemia episode within 6 months
5	CANTATA-M (NCT01081834)	Efficacy, placebo- controlled	229	230			459							None (participants on antihyperglycaemic agents as per inclusion criteria discontinued these)	HbA1c change from baseline to 26 weeks	March 2010- March 2012	 Aged 18-80 Main study: HbA1c ≥7% and ≤10% on no antihyperglycaemic agent/HbA1c ≥6.5% and ≤9.5% on antihyperglycaemic agent monotherapy or combined low dose metformin and sulfonylurea; FPG ≤15mmol/L High Glycaemic Substudy: HbA1c >10% and ≤12% and FPG ≤19.4mmol/L Exclusion: eGFR <50mL/min Treatment with PPAR-γ agonist, insulin, another SGLT2-inhibitor or any other antihyperglycaemic agents except as specified above within 12 weeks Cardiovascular disease including MI, unstable angina, revascularisation procedure or cerebrovascular accident within 3 months Hereditary glucose-galactose malabsorption or primary renal glucosuria Severe hypoglycaemia episode within 6 months
6	Efficacy, Safety, and Tolerability of Canagliflozin vs. Placebo in the Treatment of Older Subjects (NCT01106651)	Efficacy, placebo- controlled	236	228			303							Any (usual care)	HbA1c change from baseline to 26 weeks	April 2010- November 2011 (core period) or June 2013 (78- week extension)	 Aged 55-80 (women at least 3 years postmenopausal) HbA1c 27% and \$10% BMI ≥20 and \$40kg/m² Fasting fingerstick blood glucose ≥6.1mmol/L Exclusion: Uncontrolled hyperglycaemia defined as repeated FPG ≥15mmol/L Uncontrolled hyperglycaemia defined as repeated FPG ≥15mmol/L Uncontrolled hyperglycaemia defined as repeated FPG ≥15mmol/L On metformin and serum creatinine ≥124 µmol/L (men) or ≥115 µmol/L (women) Cardiovascular disease including MI, unstable angina, revascularisation procedure or cerebrovascular accident within 3 months History of New York Heart Association Class III–IV cardiac disease Severe hypoglycaemia episode within 6 months
7	CANTATA-MSU (NCT01106625)	Efficacy, placebo- controlled	149	154			303							Combined metformin and sulfonylurea at maximum- or near- maximum doses (adjusted pre-run in if not already at these doses)	HbA1c change from baseline to 26 weeks	April 2010- April 2012	 Aged 18-80 HbA1c ≥7% and ≤10.5% Currently treated with combined metformin and sulfonylurea Exclusion: Uncontrolled hyperglycaemia defined as repeated FPG ≥15mmol/L Uncontrolled hypertension eGFR <55mL/min (or <60 mL/min if based upon restriction in local label) or serum creatinine ≥124 µmol/L (men) or ≥115 µmol/L (women) Treatment with any other antihyperglycaemic agents except metformin and sulfonylurea within 12 weeks Severe hypoglycaemia episode within 6 months
8	EMPA-REG PIO (BI1245.19; NCT01210001)				159	162	321							Pioglitazone alone or in combination with metformin	HbA1c change from baseline to 24 weeks (for any background therapy and for pioglitazone + metformin subset)	September 2010-April 2012	 Aged 18+ BI1245.19: HbA1c ≥7% and ≤10%; BI1245.23: ≤11% for randomised arm, >11% for open-label arm BMI ≤45kg/m² Current treatment matches trial background therapy Exclusion: Uncontrolled hyperglycaemia after overnight fast during placebo run-in eGFR <30mL/min at screening/placebo run-in Current treatment with systemic steroids or change in dosage of thyroid hormones within 6 weeks or any
9	EMPA-REG METSU (BI1245.23; NCT01159600)	Efficacy, placebo- controlled			434	581	1,015							Immediate-release metformin (≥1500mg/day or maximum dose) alone or in combination with sulfonylurea (≥half maximum dose)	HbA1c change from baseline to 24 weeks	July 2010- February 2012	uncontrolled endocrine disorder except T2D • Treatment with anti-obesity medication/other treatment leading to unstable body weight • MI, stroke, TIA within 3 months • Bariatric/other GI surgeries within 2 years • History of cancer • Any disorders causing haemolysis or unstable red blood cells
10	EMPA-REG OUTCOME (B1245.25; NCT01131676)	CV outcomes, placebo- controlled			1,100	1,110	2,210							Any (usual care)	Time to first occurrence of 3- point MACE (composite of CV death, non-fatal MI, and non-fatal stroke)	July 2010-April 2015	 Aged 18+ HbA1c ≥7% and ≤10%, or ≥7% and ≤9% if drug-naïve BMI ≤45kg/m² High cardiovascular risk defined as ≥1 of the following (all >2 months prior): history of MI; evidence of single-vessel or multi-vessel coronary artery disease; unstable angina with evidence of single- or multi-vessel coronary artery disease; history of stroke (ischemic or hemorrhagic); occlusive peripheral artery disease Exclusion: Uncontrolled hyperglycaemia after overnight fast during placebo run-in eGFR <30mL/min at screening/placebo run-in Planned cardiac surgery or angioplasty within 3 months Current treatment with systemic steroids or change in dosage of thyroid hormones within 6 weeks or any uncontrolled endocrine disorder except T2D Treatment with anti-obesity medication/other treatment leading to unstable body weight Acute coronary syndrome, stroke, TIA within 2 months Bariatric/other GI surgeries within 2 years History of cancer Any disorders causing haemolysis or unstable red blood cells
11	Linagliptin in Combination With Metformin and a Sulfonylurea (BI1218.18; NCT00602472)	Efficacy, placebo- controlled										774	774	Combined metformin (≥1500mg/day or maximum dose) and sulfonylurea (maximum dose)	HbA1c change from baseline to 24 weeks	February 2008-May 2009	 Aged 18-80 HbA1c ≥7% and ≤10% BMI ≤40kg/m² Current treatment matches trial background therapy Exclusion: Renal failure, or renal impairment defined as serum creatinine ≥1.5 mg/dL Treatment with TZD, GLP-1 analogue, or insulin within 3 months Treatment with anti-obesity drugs (sibutramine, rimonabant, orlistat) within 3 months Current treatment with systemic steroids or change in dosage of thyroid hormones within 6 weeks MI, stroke, TIA within 6 months Dehydration Current acute or chronic metabolic acidosis
12	Efficacy and Safety of Linagliptin vs. Placebo (BI1218.16; NCT00621140)	Efficacy, placebo- controlled										326	326	None (participants on antihyperglycaemic agents as per inclusion criteria discontinued these)	HbA1c change from baseline to 24 weeks	February 2008-May 2009	 Aged 18-80 HbA1c ≥6.5% and ≤9%, or ≥7% and ≤10% if treatment-naïve Exclusion: Treatment with >1 oral antidiabetic agent within 10 weeks Treatment with TZD, GLP-1 analogue, or insulin within 3 months Treatment with anti-obesity drugs (sibutramine, rimonabant, orlistat) within 3 months Current treatment with systemic steroids or change in dosage of thyroid hormones within 6 weeks MI, stroke, TIA within 6 months
13	Efficacy and Safety of Linagliptin vs. Placebo Added to Metformin Background Therapy (BI1218.17; NCT00601250)	Efficacy, placebo- controlled										506	506	Metformin monotherapy (≥1500mg/day or maximum dose). (Participants on an additional oral antidiabetes agents as per inclusion criteria discontinued these.)	HbA1c change from baseline to 24 weeks	January 2008- May 2009	 Aged 18-80 HbA1c ≥6.5% and ≤9% if undergoing wash-out of previous medication, or ≥7% and ≤10% otherwise BMI ≤40kg/m² Currently treated with metformin (maximum dose) alone or combined with another oral antidiabetes agent Exclusion: Renal failure or renal impairment Treatment with TZD, injectable GLP-1 analogue, or insulin within 3 months Treatment with anti-obesity drugs (sibutramine, rimonabant, orlistat) within 3 months Current treatment with systemic steroids or change in dosage of thyroid hormones within 6 weeks MI, stroke, TIA within 6 months Unstable or acute congestive heart failure Dehydration History of acute or chronic metabolic acidosis Hereditary galactose intolerance
14	Efficacy and Safety of Linagliptin in Combination With Metformin (BI1218.20; NCT00622284)	Efficacy, placebo- controlled and active comparator (sulfonylurea)										759	759	Metformin monotherapy (≥1500mg/day or maximum dose). (Participants on an additional oral antidiabetes agents as per inclusion criteria discontinued these.)	HbA1c change from baseline to 52 weeks	February 2008- December 2010	 Aged 18-80 HbA1c ≥6% and ≤9% if treated with metformin and another oral antidiabetes agent,, or ≥6.5% and ≤10% if treated with metformin alone BMI ≤40kg/m² Currently treated with metformin (maximum dose) alone or combined with another oral antidiabetes agent Exclusion: Renal failure or renal impairment Treatment with TZD, GLP-1 analogue, or insulin within 3 months MI, stroke, TIA within 6 months

BMI, body mass index; DPP4-i(nhibitor), dipeptidyl-peptidase 4 inhibitor; eGFR, estimated glomerular filtration rate; FPG, fasting plasma glucose; GLP-1, glucagon-like peptide-1; HbA1c, glycated haemoglobin, type A1c; MACE, major adverse cardiovascular event; MI, myocardial infarction; PPAR-y, peroxisome proliferator-activated receptor gamma ; SGLT2-i(nhibitor), sodium-glucose cotransporter-2 inhibitor; t2D, Type 2 diabetes; TIA, transient ischaemic attack; TZD, thiazolidinedione.

¹Ns are participants included in the mixed effects models and subsequent meta-analysis. This includes participants who were not insulin-treated and with at least one on-treatment HbA1c between randomisation and 6 months (trials 3,8,9: HbA1c measurements excluded after changes in study medication (including dose changes); trial 10: HbA1c measurements excluded after changes in study medication (including dose changes); trial 10: HbA1c measurements excluded after changes in study medication (including dose changes); trials 1,2,4-7: treatment group is as randomised; trials 3,8-14: treatment group is actual study medication given.

²All trials:

Diagnosis of Type 2 diabetes mellitus
Background therapy as stated in table and unchanged for up to 12 weeks prior to randomisation (varies between trials)
Exclusion:

• (Symptoms of) Type 1 diabetes mellitus or other type of diabetes mellitus

• Contraindications (according to local market) to assigned background or study medications

• Liver disease defined by elevated ALT, AST and/or alkaline phosphatase

Nursing or pregnant women; or premenopausal women of child bearing potential either intending to become pregnant during the trial period and/or not practicing an acceptable method of birth control
 History of alcohol or drug abuse
 Participation in another trial with an investigational drug within preceding 30 days

• Any other clinical condition that would jeopardise patient safety while participating in this clinical trial